Sotera Health Company (NasdaqGS:SHC) Q4 2025 Earnings call February 24, 2026 09:00 AM ET Company ParticipantsDavid Windley - Managing Director and Founding Member of Healthcare Equity Research TeamJason Peterson - VP of Investor Relations and TreasuryJonathan M. Lyons - CFOMichael Petras - Chairman and CEOSam Eiber - Equity Research AssociateConference Call ParticipantsBrett Fishman - VP and Senior Equity Research AnalystCasey Woodring - VP and Senior Equity Research AnalystChristine Rains - Healthcare Equi ...

Financial Data and Key Metrics Changes - Total company revenue increased by 5.7% to $1.164 billion in 2025, or 5.2% growth on a constant currency basis compared to 2024 [5][15] - Adjusted EBITDA rose by 8.2% to $593.8 million, or 7.8% on a constant currency basis, with margins expanding to 51%, an increase of 118 basis points [5][15] - Adjusted EPS for the year was $0.86, an increase of $0.16 versus 2024, driven by operational growth and a lower tax rate [16] Business Line Data and Key Metrics Changes - Sterigenics revenue improved by 10.6% to $198 million, or 8% on a constant currency basis, driven by favorable pricing and volume [12] - Nordion's revenue decreased by 12.3% to $50 million due to unfavorable volume and mix from Cobalt-60 harvest timing [13] - Nelson Labs revenue increased by 2.3% to $55 million, with favorable pricing and core lab testing growth partially offset by lower advisory services revenue [14] Market Data and Key Metrics Changes - Customer satisfaction exceeded 80%, indicating strong service delivery [6] - Revenue from XBU customers expanded by 9% year-over-year, reflecting successful cross-selling initiatives [6][50] Company Strategy and Development Direction - The company aims to execute its 2025-2027 long-range plan, focusing on operational excellence, disciplined capital deployment, and enhancing free cash flow [8][21] - The construction of a new X-ray facility is planned to open in 2026, which is part of a strategic investment to expand service offerings [6][44] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to drive long-term growth and shareholder value, emphasizing strong cash flow generation and customer relationships [21][105] - The company expects total revenue for 2026 to be in the range of $1.233 billion to $1.251 billion, representing 5%-6.5% constant currency growth [9][18] Other Important Information - The company reduced borrowing costs by 75 basis points on its $1.4 billion term loan and paid down $86 million of debt, resulting in annual interest savings of $13 million [7] - The company has approximately $940 million of available liquidity as of December 31, 2025 [16] Q&A Session Summary Question: Guidance and EBITDA margins - Management indicated that the expected EBITDA margin expansion is primarily due to normal operating leverage without any unusual dynamics [23][24] Question: Sterigenics client insourcing - Management noted that while one client is transitioning back to outsourcing, significant shifts in the market are not yet observed due to extended compliance periods [25][26] Question: 2026 outlook for Sterigenics - Management expects mid to high single-digit constant currency revenue growth for Sterigenics in 2026, with a soft start anticipated in Q1 [18][32] Question: Nelson Labs margins - Management expects Nelson Labs to maintain margins in the low to mid 30% range, with Q1 typically being the softest quarter [34][35] Question: Nordion segment headwinds - Management clarified that Nordion's challenges were due to Cobalt-60 harvest timing rather than demand issues [84][85] Question: Competitive positioning in Sterigenics - Management believes Sterigenics is well-positioned despite the extended compliance period, with strong customer satisfaction scores [68][69] Question: Impact of onshoring - Management has not seen significant movement towards onshoring but is prepared for potential shifts in the market [87] Question: Volume and mix visibility - Management indicated that volume and mix are key factors that could drive performance towards the higher end of guidance [91][92]

Sotera Health Company (NasdaqGS:SHC) Q4 2025 Earnings call February 24, 2026 09:00 AM ET Speaker9Please note this event is being recorded. I would now like to turn the conference over to Vice President of Investor Relations, Jason Peterson. Jason, please go ahead.Speaker5Good morning. Thank you. Welcome to Sotera Health's fourth quarter and full year 2025 earnings call. Today's press release and supplemental slides are available on the investor section of our website at soterahealth.com. This webcast is bei ...

Achieved a significant milestone by exceeding $1 billion in annual revenue, effectively quadrupling the business over the last five years through a focus on long-term shareholder value. Performance was driven by the successful onboarding of large enterprise customers, which contributed to higher-than-anticipated revenue and contribution profit per transaction in the fourth quarter. Management attributes growth to a state-of-the-art platform that replaces legacy bank bill pay and in-house infrastructur ...

Performance was characterized by a sharp divergence between stable 2.9% traffic growth in Mexico and a 35% quarterly decline in Jamaica following Hurricane Melissa. Revenue growth of 12.8% was primarily decoupled from traffic volume, driven instead by the implementation of new maximum tariffs approved for the Mexican portfolio in 2025. The Jamaican downturn is attributed to the loss of approximately 70% of hotel infrastructure capacity surrounding Montego Bay rather than physical damage to airport fac ...

24 February 2026 - Fleet utilisation for January 2026 was 100%. In Brazil, Safe Eurus, Safe Notos, and Safe Zephyrus continued to operate at full capacity in January, delivering near 100 % commercial uptime. Safe Caledonia maintained 100% commercial uptime at the Captain Field in the UK. The vessel ended the contract for Ithaca Energy on 22 February 2026 following the exercise of all option periods. The vessel has a Letter of Intent (LoI) from Ithaca Energy for 6 months firm and 3 months of options from t ...

Toronto, Ontario--(Newsfile Corp. - February 23, 2026) - THS Maple Holdings Ltd. (TSXV: YAY) (the "Company" or "THS"), a leading producer and global distributor of maple syrup and maple-flavoured products, is pleased to announce its financial and operational results for the three and six-month periods ended December 31, 2025. The results highlight the Company's commitment to deploying and executing its short- and medium-term strategic initiatives and in investing in its market presence expansion. Financial ...

BioMarin Pharmaceutical (NasdaqGS:BMRN) Q4 2025 Earnings call February 23, 2026 04:30 PM ET Speaker10Thank you for standing by. My name is Kate, and I will be your conference operator today. At this time, I would like to welcome everyone to the BioMarin Pharmaceutical fourth quarter and full year 2025 conference call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question and answer session. If you would like to ask a question during this ti ...

Key Takeaways VLY's 2025 revenues climbed to $2.03B, lifted by strong NII and fee income growth.Valley National saw NIM rebound in 2025 on lower funding costs and deposit growth.VLY projects 11-13% NII growth in 2026, with 4-6% loan growth and margin expansion.Valley National Bancorp (VLY) reported a 9.3% year-over-year increase in 2025 total revenues to $2.03 billion. The growth was primarily driven by a substantial increase in net interest income (NII), supported by higher average loan balances and a nota ...

Core Viewpoint - Tilray Brands is struggling to achieve profitability despite its diverse product offerings in the beverage, cannabis, and wellness industries, with significant competition and ongoing losses impacting its financial performance [1][4]. Group 1: Financial Performance - Tilray Brands' stock price has decreased by 99% from its all-time high, reflecting investor fatigue over the company's inability to generate profits [4]. - The company has been expanding aggressively into other areas, particularly alcohol, but this strategy has not yet resulted in positive earnings [4]. Group 2: Revenue Growth and Strategy - Tilray is focusing on revenue growth through aggressive brand acquisitions since 2021, which has led to increased revenue and potential synergies [5]. - However, the rising share count due to stock sales for cash or acquisitions is diluting existing shareholders and complicating profit generation [6]. Group 3: Investment Risks - The ongoing losses and aggressive acquisition strategy present high risks for investors, with the company having to take write-downs across all divisions [7]. - Investors are advised to be cautious and may benefit from observing the company's performance before committing capital [7].